Abstract
RATIONALE: IL1-β inhibition with weekly rilonacept provides marked/durable improvement in clinical symptoms associated with Familial Cold Auto-inflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS) while exhibiting an acceptable safety/tolerability profile. Results described herein provide evidence of the rapid onset of action of rilonacept in FCAS/MWS patients.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
